Bristol-myers Squibb

This study is testing a new drug called BMS-986435/MYK-224 in adults with a specific type of heart failure where the heart pumps normally but still causes symptoms. The main goals are to check the drug's safety, how well people tolerate it, and how it behaves in the body. About 2…

This early-stage study is testing a new drug called BMS-986460 in men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. The main goal is to check the drug's safety and side effects in about 140 participants. Researchers will also…

This study is testing a new drug called pumitamig, both by itself and combined with an existing drug (ipilimumab), for people with advanced liver cancer that cannot be removed by surgery. The main goals are to see if these treatments are safe and if they can shrink tumors. It is …

This study allows patients with lupus who completed two previous trials to continue taking the medication deucravacitinib. The goal is to maintain disease control for those who benefited from the drug. Only 35 participants who finished the earlier studies are eligible to join.

This study is observing how a drug called luspatercept works for adults with severe beta-thalassemia in the Middle East. The goal is to see if the drug can help patients need fewer blood transfusions and improve their hemoglobin levels. Researchers will follow 200 patients who ar…

This study is testing an investigational drug called luspatercept to see if it can help people with a genetic blood disorder called alpha-thalassemia. The main goal is to see if the drug can safely reduce the need for frequent blood transfusions in adults who require them and inc…

This study is testing whether adding an investigational medication called KarXT to standard mood stabilizers helps reduce manic symptoms in people with Bipolar I disorder. Researchers will compare KarXT against a placebo in 424 hospitalized adults currently experiencing a manic e…

This study is testing whether an oral medication called deucravacitinib can safely and effectively treat moderate-to-severe plaque psoriasis in teenagers aged 12-17. Researchers will compare the drug against a placebo pill in 366 adolescent participants to see if it significantly…

This early-stage trial is testing a new cancer drug called BMS-986517 in adults with advanced solid tumors that have spread or cannot be surgically removed. The main goals are to determine if the drug is safe, what side effects it causes, and what dose works best. Researchers wil…

This early-stage trial is testing a new oral medication called BMS-986506 for people with advanced kidney cancer. The main goal is to determine if the drug is safe and tolerable for patients who have already tried other treatments. Researchers will enroll 125 participants to find…

This study is testing two different dosing schedules for a new, injectable form of an immunotherapy drug (nivolumab) given under the skin. It is combined with another immunotherapy drug (ipilimumab) and standard chemotherapy. The goal is to see how the body processes the drugs an…

This study is testing whether a new drug called pumitamig works better than the current standard drug nivolumab when both are given with chemotherapy. It's for people with advanced stomach or esophageal cancer who haven't had previous treatment. The trial will measure how well tu…

This early-stage study is testing a new drug called BMS-986470 in healthy volunteers and people with sickle cell disease. Researchers want to understand if the drug is safe, how it moves through the body, and whether it can help increase healthy hemoglobin levels in sickle cell p…

This is the first human trial of a new cancer drug called BMS-986484. Researchers are testing it alone and combined with an existing immunotherapy (nivolumab) in 213 people with advanced solid tumors, including lung, pancreatic, and colorectal cancers. The main goal is to find sa…

This study is testing an oral drug called BMS-986504 for people with advanced non-small cell lung cancer that has a specific genetic change called an MTAP deletion and has worsened after prior treatments. The main goals are to see if the drug is safe and if it can shrink tumors o…

This study is testing whether a two-drug combination called KarXT + KarX-EC can help improve thinking and memory problems in people with mild to moderate Alzheimer's disease. Researchers will compare the drug combination against a placebo in 586 participants over several months t…

This study tracks the long-term safety of nivolumab (Opdivo) cancer treatments for patients who previously participated in Bristol-Myers Squibb trials. It allows 1,500 cancer patients who responded well to continue receiving treatment while researchers monitor for any side effect…

This study is testing a new drug called pumitamig, both by itself and in combination with two other cancer drugs, for people with advanced kidney cancer that has spread. The main goals are to see if the treatments are safe and if they can shrink tumors. The trial will enroll abou…

This study is testing if switching teenage kidney transplant patients from their current standard anti-rejection pills to a newer monthly infusion drug (belatacept) is better for their long-term kidney health. Researchers will compare the two groups over two years to see which pl…

This study looks at how well two different drugs, ozanimod and azathioprine, work for people with ulcerative colitis who need steroids to manage their disease. Researchers will review the medical records of 150 patients in Japan to see which drug is better at helping patients ach…

This study is testing a new drug called BMS-986458 to see if it is safe and can help control non-Hodgkin lymphoma that has returned or hasn't responded to previous treatments. It will involve about 308 adults and will test the drug by itself and combined with other lymphoma medic…

This program provides access to the investigational drug iberdomide for eligible patients who cannot join clinical trials. It allows patients to receive the medication outside of a formal study setting. The program is managed by Bristol-Myers Squibb and is currently available.

This study is testing whether a new drug called izalontamab brengitecan works better than standard chemotherapy for people with advanced lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to their current targeted therapy. The trial will inv…

This study aims to understand the long-term safety of KarXT medication for people with bipolar disorder who experience manic episodes. The research will follow 450 participants for an extended period to monitor side effects and how well the treatment is tolerated. The goal is to …

This study is testing a new targeted drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative or low-estrogen breast cancer who cannot receive common immunotherapies. The goal is to see if the new drug can better control the cance…

This study is testing a new drug called BMS-986482 to see if it is safe and effective for treating advanced solid tumors. It will involve about 413 adults whose cancer has progressed despite standard treatments. The drug will be tested both by itself and in combination with other…

This study is testing an existing heart medication called mavacamten in Indian adults with a genetic heart condition that causes the heart muscle to thicken and obstruct blood flow. Researchers want to see how safe and effective the drug is specifically for this population over 3…

This trial is testing whether a new drug combination called izalontamab brengitecan works better than standard chemotherapy for people with advanced bladder cancer that has stopped responding to immunotherapy. About 470 participants will receive either the experimental drug or ch…

This study is testing whether an oral medication called ozanimod can help children with moderate-to-severe ulcerative colitis achieve and maintain remission. It is for kids whose symptoms haven't improved enough with standard treatments. Researchers will measure how well the drug…

This is a first-in-human study to test the safety and dosing of an experimental drug called BMS-986500. It will be given alone to people with various advanced solid tumors and in combination with other drugs to people with advanced breast cancer that has stopped responding to pri…

This study is testing whether the medication KarXT can help control symptoms of schizophrenia in teenagers aged 13-17. Researchers will measure how well it reduces symptoms like hallucinations, delusions, and social withdrawal compared to a placebo. The trial involves 166 partici…

This study follows 200 Italian patients with moderate to severe psoriasis who have recently started taking the medication deucravacitinib. Researchers want to see how well the drug works, how safe it is, and how it affects patients' quality of life in a real-world setting, outsid…

This study is testing whether a new two-drug combination works better than current standard treatment for extensive-stage small cell lung cancer. Researchers will compare how long patients live and how well they tolerate the treatments. The trial involves 530 participants who hav…

This study aims to see if a new drug called iberdomide is better than the current standard drug, lenalidomide, at keeping multiple myeloma from coming back after a patient's own stem cell transplant. It will involve over 1,200 people recently diagnosed with this blood cancer. The…

This study is testing whether an investigational drug called KarXT can help control severe manic episodes in people with Bipolar-I disorder. Researchers will compare KarXT against a placebo in about 274 hospitalized adults experiencing an acute manic episode over a 3-week treatme…

This early-stage trial is testing a new drug called BMS-986497 for adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or resisted previous treatments. Researchers will give the drug alone and in combination with two standard cancer medications to fin…

This early-stage study is testing a new drug called BMS-986523, both alone and combined with other cancer treatments, in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check if the drug is safe, how the body processes it,…

This study aims to compare the long-term safety of two psoriasis medications—deucravacitinib and ustekinumab—in people with moderate-to-severe plaque psoriasis who also have cardiovascular risk factors. Researchers will follow 3,040 participants for several years to track serious…

This study is testing whether adding an experimental drug called BMS-986504 to standard chemotherapy works better than chemotherapy alone for people with advanced pancreatic cancer that has spread and has a specific genetic change (MTAP deletion). The trial will involve about 470…

This early-stage study is testing a new oral drug called BMS-986504 in Japanese and Chinese patients with advanced solid tumors that have a specific genetic deletion called MTAP. The main goals are to check how safe the drug is, how well patients tolerate it, and how the drug mov…

This early-stage study is testing a new drug combination called BMS-986507 in adults with advanced lung or breast cancer that has spread. The main goals are to find a safe dose and see how the body processes the drug, while also looking for early signs that it might help control …

This study is monitoring the real-world safety and effectiveness of the drug mavacamten in Japanese patients with obstructive hypertrophic cardiomyopathy (oHCM), a condition where the heart muscle thickens and obstructs blood flow. It will enroll about 200 patients who are prescr…

This study is testing whether the drug KarXT can help control symptoms during severe manic episodes in people with Bipolar-I disorder. About 274 hospitalized adults will receive either KarXT or a placebo (inactive pill) for 3 weeks while researchers measure changes in their manic…

This study is testing whether a new drug called pumitamig, when added to standard chemotherapy, works better than the current standard treatment for advanced colorectal cancer. It will involve about 990 adults whose cancer has spread and cannot be removed by surgery, and who have…

This study aims to check the long-term safety of the schizophrenia medication KarXT, specifically looking at how it might affect bladder function. It will follow 60 adults with stable schizophrenia for 12 months while they take the drug. The main goal is to see if KarXT causes an…

This study is testing a new drug called BMS-986525, both by itself and combined with an existing immunotherapy drug (nivolumab), for people with small cell lung cancer that has come back or stopped responding to standard chemotherapy. The main goals are to see if the treatments a…

This study aims to see how well the medication deucravacitinib works for adults with moderate plaque psoriasis in everyday medical practice in China. It will follow 150 patients who are newly starting this treatment to measure improvements in their skin condition and quality of l…

This study is testing whether a medication called KarXT can help control symptoms in Japanese adults experiencing acute schizophrenia episodes. The trial has two parts: first, 250 participants will receive either KarXT or a placebo for 5 weeks, followed by a year-long extension w…

This is an early safety study for a new drug called BMS-986326 for people with different types of lupus. The main goal is to see if the drug is safe and how the body processes it when given in increasing doses. Researchers will also check if the drug affects certain immune cells …

This study is testing a new drug called BMS-986340 to see if it is safe and can help control advanced cancers. It will be given alone or combined with two other cancer drugs to about 950 people whose cancers have grown despite standard treatments. The main goal is to find the rig…

This study aims to find out if a new drug combination called KarXT + KarX-EC can help control the memory and thinking problems caused by mild to moderate Alzheimer's disease. It will involve about 586 people who have been diagnosed with Alzheimer's and will compare the effects of…

This study is testing an oral medication called deucravacitinib in children and teenagers aged 4 to 18 who have moderate to severe plaque psoriasis. The goal is to find the right dose for kids and see how well it clears their skin and how safe it is over time. The trial includes …

This is the first human study of an experimental drug called BMS-986463 for people with advanced ovarian, uterine, or lung cancers. The main goal is to find safe dose levels and see how the body processes the drug. Researchers will enroll about 240 participants to monitor side ef…

This study is testing whether adding an experimental drug called BMS-986504 to standard immunotherapy and chemotherapy works better than standard treatment alone for people with advanced lung cancer that has spread and has a specific genetic deletion called MTAP. The trial will i…

This early-stage clinical trial is testing a new experimental drug called BMS-986490, both alone and combined with an existing cancer drug (bevacizumab), for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to determine if the …

This is the first study in people of an experimental pill called MRTX1719. It is for adults with advanced solid tumors that have a specific missing gene called MTAP, which is found in some lung cancers, mesothelioma, and other cancers. The main goals are to find a safe dose, see …

This study aims to see how well the medication mavacamten works for Chinese adults who have a condition where their heart muscle is abnormally thick, making it harder for the heart to pump blood. It will follow 500 patients in real-world doctor's offices, not a controlled lab set…

This program provides access to the investigational drug mezigdomide for eligible patients who cannot participate in clinical trials. It's designed for people who may benefit from the treatment but don't qualify for ongoing studies. The program allows patients to receive the medi…

This study is testing a pill called deucravacitinib to see if it can control joint pain, swelling, and skin symptoms in children and teenagers with juvenile psoriatic arthritis. It will involve about 60 participants aged 5 to 18 who have tried other treatments that didn't work we…

This study is testing new combinations of experimental drugs for people with multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find safe doses and see if these combinations can help control the cancer. The study will enroll about…

This large Phase 3 trial aims to determine if a new combination of two immunotherapy drugs (nivolumab + relatlimab) plus chemotherapy works better than the current standard treatment (pembrolizumab + chemotherapy) for people with advanced non-small cell lung cancer. The study wil…

This study is observing adults with schizophrenia who are switching to a newer medication called KarXT. It aims to see how well the drug works and what side effects people experience in real-world settings, outside of a controlled clinical trial. Researchers will follow 1500 part…

This early-stage study is testing a new long-acting injectable medication called KarXT for schizophrenia. The main goal is to find safe dose levels and understand how the drug moves through the body. It involves 48 adults with stable schizophrenia who will receive a single inject…

This study aims to see if a newer drug called luspatercept works better and is safer than the standard drug epoetin alfa for treating anemia in adults with lower-risk myelodysplastic syndromes (MDS). It will enroll 360 participants who have not yet taken similar anemia drugs and …

This study is testing whether a combination of two medications called KarXT and KarX-EC can safely reduce agitation in people with Alzheimer's disease. The trial will involve 352 adults with Alzheimer's who experience significant agitation, comparing the active treatment to a pla…

This study aims to understand the long-term safety and side effects of two drug combinations, KarXT and KarX-EC, for treating agitation in people with Alzheimer's disease. It is open to 600 participants who have already completed one of two previous related studies. The main goal…

This study is testing whether a combination of two medications, KarXT and KarX-EC, can safely reduce agitation in people with Alzheimer's disease. The trial will involve 352 adults who experience significant agitation related to their Alzheimer's. Participants will receive either…

This early-stage study aims to check if an experimental drug called BMS-986278 affects the heart's electrical rhythm. Researchers will give the drug to 32 healthy adults and carefully monitor their heart activity. The main goal is to gather safety data before testing the drug in …

This study aims to understand how well current standard treatments work for people with active systemic lupus erythematosus (SLE), including lupus affecting the kidneys, who haven't responded well to steroids and at least two other immune-suppressing drugs. Researchers will obser…

This study aims to understand how and why elderly patients in Italy with a common heart rhythm problem (atrial fibrillation) are prescribed blood thinners. It will follow 720 patients for one year to see which treatments doctors choose, how often patients switch or stop their med…

This study aims to understand what patients and their doctors value most when choosing treatments for early-stage, operable lung cancer. Researchers will conduct short interviews with 55 patients and physicians from the US, Germany, and Japan. The goal is to gather insights to he…

This study aims to understand the daily experiences, quality of life, and unmet needs of people in Japan living with a low-risk form of myelodysplastic syndrome (a bone marrow disorder) or unexplained anemia. Researchers will survey and interview approximately 50 participants who…

This study aims to gather safety information for pregnant women with multiple sclerosis who take the medication ozanimod. Researchers will follow about 1,200 women in the US, Canada, and Germany to track health outcomes for both the mothers and their babies. The goal is to help f…

This study aims to understand the safety of the heart medication mavacamten during pregnancy and breastfeeding. Researchers will follow about 20 people who took the drug while pregnant or nursing, tracking the health of both the parent and baby for up to a year after birth. This …

This early-stage study aims to understand how the body processes new versions of the drug combination KarXT. It will involve 72 healthy adult volunteers to measure drug levels in the blood and check for safety. Researchers will compare new pill forms to existing ones and see if t…

This early-stage study aims to understand how the body absorbs different tablet versions of an experimental drug called BMS-986435. It will also test if eating food affects how the chosen tablet works. The study involves 140 healthy adult volunteers to gather basic safety and abs…

This is the first study in humans to test the safety and drug levels of a new oral medication called BMS-986521. Healthy adult volunteers will take single and multiple doses to see how their bodies handle the drug and check for side effects. The study will also examine whether ta…

This study is a large registry that aims to observe and collect information on how patients with a specific heart condition called obstructive hypertrophic cardiomyopathy (HCM) are treated and how they fare over time in the real world. It will follow 1,600 adults in the US and Eu…

This study is a testing service, not a treatment. It aims to analyze tumor samples from patients who received a specific Bristol-Myers Squibb gene therapy for blood cancers and later developed a second, unrelated cancer. The goal is to check if genetic material from the original …

This study aims to understand how satisfied adults with schizophrenia are with a new medication called KarXT (xanomeline and trospium chloride) in their daily lives. It will follow 300 participants in the U.S. who are starting this treatment, asking them about their medication pr…